Download PDF
Thromb Haemost 1981; 45(01): 096
DOI: 10.1055/s-0038-1650138
Letter to the Editor
Schattauer GmbH Stuttgart

Inhibitor to Factor IX Following Activated Prothrombin-Complex Concentrate Treatment

F Panicucci
Centre for the Study and Treatment of Haemophilia and Haemorrhagic Disorders, University of Pisa, St. Chiara Hospital, Pisa, Italy
,
A Sagripanti
Centre for the Study and Treatment of Haemophilia and Haemorrhagic Disorders, University of Pisa, St. Chiara Hospital, Pisa, Italy
,
B Conte
Centre for the Study and Treatment of Haemophilia and Haemorrhagic Disorders, University of Pisa, St. Chiara Hospital, Pisa, Italy
,
E Pinori
Centre for the Study and Treatment of Haemophilia and Haemorrhagic Disorders, University of Pisa, St. Chiara Hospital, Pisa, Italy
,
M Vispi
Centre for the Study and Treatment of Haemophilia and Haemorrhagic Disorders, University of Pisa, St. Chiara Hospital, Pisa, Italy
› Author Affiliations
Further Information

Publication History

Received 05 November 1980

Accepted 29 November 1980

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Mannucci PM, Bader R, Ruggeri ZM. Concentrates of clotting-factor IX. Lancet 1976; 1: 41
    PubMedGoogle Scholar
  • 2 Preston RCM, Disadale DJ, Sutcliffe GB, Wyld PJ, Hamlyn JP. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thrombosis Res 1977; 11: 643-651
    CrossrefPubMedGoogle Scholar
  • 3 Lechner K, Nowotny C, Krinninger B, Zagner M, Deutsch E. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor Vlll-antibody level. Thromb Haemostas 1979; 40: 478
    PubMedGoogle Scholar
  • 4 Stenbjerg S, Jorgensen J. Disseminated intravascular coagulation and infusion of factor-Vlll-inhibitor bypassing activity. Lancet 1977; 1: 360
    PubMedGoogle Scholar
  • 5 Anderle K. The clinical application of FEIBA Immuno in factor VIII inhibitor patients. Thromb Haemostas 1977; 38: 347
    PubMedGoogle Scholar
  • 6 Stenbjerg S, Jorgensen J. Resistance to activated F IX concentrate (FEIBA) Scand. J Haematol 1977; 18: 421-426
    PubMedGoogle Scholar